Previous close | 0.1500 |
Open | 0.1450 |
Bid | 0.1400 x 1582700 |
Ask | 0.1500 x 3535900 |
Day's range | 0.1450 - 0.1450 |
52-week range | 0.1300 - 0.4450 |
Volume | |
Avg. volume | 231,111 |
Market cap | 26.047M |
Beta (5Y monthly) | 0.70 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.0700 |
Earnings date | 22 Aug 2023 - 28 Aug 2023 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Dimension Inx, a biomaterials platform company developing therapeutics that restore tissue and organ function, announced today the appointments of Paul K. Wotton, Ph.D., to the board of directors and Chris Ehrlich as Senior Advisor.
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
The underwhelming share price performance of Cynata Therapeutics Limited ( ASX:CYP ) in the past three years would have...
Cynata Therapeutics Limited (ASX: "CYP" or "Cynata"), a clinical-stage biotechnology company specialising in cell therapeutics, is delighted to announce that the LUMC is funding an important clinical trial to investigate Cynata's Cymerus™ MSCs as a treatment for renal graft rejection and to potentially reduce the requirement for anti-rejection drugs.
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...